Caliway Received U.S. FDA Fast Track Designation for CBL-514 for the Treatment of Dercum’s Disease

– Fast Track designation indicates CBL-514’s potential in filling the unmet medical need of Dercum’s disease. – CBL-514 is the first drug to receive Fast Track designation for Dercum’s disease treatment. – CBL-514 Phase 2 study in Dercum’s disease demonstrated its efficacy in significant…